Crystal Pharmatech’s Post

Respiratory drug development demands a comprehensive understanding of both the drug's Pharmacokinetics and Pharmacodynamic nature. One of the primary roles of CROs is to design tailored methodologies for bioanalysis and collaborating closely with pharma and biopharma companies to develop and validate robust bioanalytical methods. Tune in to our latest video presentation, as we explore and address the five key challenges in method development and validation of Fluticasone Propionate and our experience with different molecules in the field of Respiratory , such as Salmeterol, Formoterol, Tiotropium, Budesonide, and more.   To know more about our Respiratory drug-development Capabilities write to us at info@veedacr.com Partners in creating a healthier tomorrow. #Veeda #VeedaClinicalResearch #VeedaCR #DrugDevelopment #RespiratoryDrug #CRO #Bioanalysis #Respiratory

CNBC recently conducted an interview with Raymond Stevens, Founder and CEO of Structure Therapeutics (NASDAQ: GPCR), where he delved into the surge in the weight loss drug market and the latest data insights from the company's own drug, GSBR-1290. Structure Therapeutics unveiled promising topline results from a 12-week Phase 2a obesity study of its oral, non-peptide GLP-1 receptor agonist, GSBR-1290, alongside favorable data from its capsule to tablet PK study. GSBR-1290 exhibited significant and clinically meaningful weight loss outcomes, coupled with generally positive safety and tolerability profiles. Raymond emphasized the scalability advantage of developing small molecule drugs, stating that when they design a molecule, scalability is a primary consideration. With this in mind, the company is able to scale up, currently reaching up to 6,000 metric tons. This amount of material can cater to over 120 million patients today. For More Information: https://lnkd.in/g662i-_4 #WeightLoss #DrugDevelopment #ClinicalTrials #ObesityResearch #DrugDiscovery #QimingPortfolio #QimingHealthcare

Read the first article in a series on the potential use of CD8 ImmunoPET in the Knowledge Hub on our website. Discover how the mechanism of action (MoA) of immuno-oncology drug candidates is shedding light on its applications in clinical trials. Click here to read: https://lnkd.in/g7EtTptB #ImaginAb #immunooncology #CD8 ImmunoPET #biotech #pharma

Are you curious about how nuclear medicine can contribute to the advancement of immunotherapy in oncology? This article elaborates on how CD8 ImmunoPET is a potential game-changer within immuno-oncology research, providing unique insights into the mechanism of action of drug candidates in clinical trials. #precisionmedicine #immunooncology #ASCO

#Article: Recent advancements in glycan analysis methods have the potential to revolutionize protein drug development. As glycosylation is a complex attribute, these innovations will provide crucial insights for researchers and manufacturers to optimize therapeutic proteins and improve patient outcomes. In this article, #TeamSCIEX members Roxana McCloskey, Senior Global Marketing Manager for Protein Therapeutics, and Zoe Zhang Ph.D., Senior Manager for Biopharma Applications, discuss glycan characterization in the context of drug development, including the importance of glycan characterization, how glycosylation impacts the drug development process, and glycan analysis methods with Jennifer Tsang, Ph.D. of Biocompare. Read the full article to learn more 👉 https://bit.ly/3tvyjak #InTheNews #SCIEXBiopharma #ProteinTherapeutics #SCIEX #SCIEXforScience #GlycanAnalysis #PrecisionMedicine #PowerOfPrecision

Intriguing insights from the Samsung Bioepis Q4 Market Report certainly shed light on the promising future of biosimilars. As we gear up for #BiosimilarWeek this November, we observe that investment in biosimilars is a transformative step towards cost-effective healthcare and enhanced accessibility: ➡️ Regulatory: As of October 2023, the FDA has granted approval for 42 biosimilars across 12 unique biological molecules, signaling a well-established reg pathway and growing market acceptance. The situation is parallel in Europe, where biosimilar #adoption was pioneered. Conducting your #BEQ studies at Biokinetica early phase unit provides convenient access to the #EU market. ➡️ Cost Savings: Increased usage of biosimilars is directly correlated with lower costs, translating into significant healthcare savings, making them a cost-effective choice for patients, healthcare systems, and insurers. ➡️ TA sensitivity: Biosimilars exhibit greater sensitivity to price changes in areas like oncology, further underlining their cost-saving potential. ➡️ Market Share: The adoption of biosimilars varies by biological molecule, but acceptance has been greater in #Oncology than other TAs. On average, biosimilars gain 53% market share in three years post initial launch. This impressive market penetration underscores the growing trust and acceptance of biosimilars among both #healthcare providers and #patients. Read more: https://lnkd.in/dFYiqXEC #biosimilardevelopment #biosimilar #bioequivalence

Stifel is pleased to share the latest Biopharma Market Report. This publication features notable industry news, a summary of related capital markets and deal activity, and a review of current research on autoantibodies. Click below to learn more: #biopharma #industrynews #dealactivity #medicalresearch #autoantibodies

Join Novotech for an informative webinar on May 8, 2024, at 3-4 pm CST, where we will explore the Bioassay Platform for Small Nucleic Acid Drug Analysis: PK, PD, and Immunogenicity. Our experts, Ian Yeh (葉斯寧) and Thomas Tang (湯偉辰), will do a deep dive into the importance of bioassays in advancing clinical drug development and meeting the demands of monitoring therapeutic drugs. Register now and gain the insights needed into one of the most dynamic areas in drug development. #Bioassay #ClinicalTrials #Novotech

On Monday, April 8, at 8 a.m. ET, we will host a conference call and webcast to share topline data from our ongoing Phase 1/2 clinical trials of INZ-701 in adults with #ENPP1 Deficiency and #ABCC6 Deficiency.    Our leadership team will also provide an update on our Natural History Study in pediatric patients with ABCC6 Deficiency and will be joined by key opinion leaders who will present an overview of the unmet need in ABCC6 Deficiency.     Learn more about how to join: https://bit.ly/3xbweBF     #RareDisease #Biotech #Biopharmaceutical 

I can't believe it’s been 15 years since STC Biologics’ creation. We are so proud to be in business for so long and to help over 170 companies with biologics development, with more than 10 products getting to the market. We started as a biosimilar company in 2009 when the pathway for their commercialization was still not sorted out, made Herceptin biosimilar - still available if anyone wants clinical ready material, then decided to pivot to biologics cdmo space when we were just a few in early 2010s without any investment. The cdmo ride has been great and we have been profitable for over 10 years. We have build a solid business with no debt and a lot of cash. We have learned how to solve many issues with biologics as we only got the difficult projects being less known. Some of them included amino acid substitutions and related amino acid deficiencies during upstream process, unexpected charge variants on stability, badly designed HCP assays and related toxicities in humans, particulates ( visible and subvisible) on stability or in a bag, tween degradation, and many others. Many of them could have been diagnosed earlier but many preferred to save money and not do long stability studies or forced degradation. We are literally 5 min from Cambridge in Newton MA and hoping to grow more by getting your drugs to the clinic at accelerated timelines! We are a local company and I hope that all of you will support local businesses since that will create wealth for our communities. Hope to see you soon. #supportlocalbusiness #stcbiologics #antibodies #cdmo #speedtoclinic<12mo